vs

Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Citizens Community Bancorp Inc. (CZWI). Click either name above to swap in a different company.

Citizens Community Bancorp Inc. is the larger business by last-quarter revenue ($15.8M vs $10.7M, roughly 1.5× Arbutus Biopharma Corp). Citizens Community Bancorp Inc. runs the higher net margin — 27.1% vs 23.5%, a 3.6% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 14.9%). Over the past eight quarters, Citizens Community Bancorp Inc.'s revenue compounded faster (1.9% CAGR vs -13.2%).

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

Glacier Bancorp, Inc. is a regional multi-bank holding company headquartered in Kalispell, Montana, United States. It is a successor corporation to the Delaware corporation originally incorporated in 1990. The company provides personal and commercial banking services from 221 locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, and, Nevada.

ABUS vs CZWI — Head-to-Head

Bigger by revenue
CZWI
CZWI
1.5× larger
CZWI
$15.8M
$10.7M
ABUS
Growing faster (revenue YoY)
ABUS
ABUS
+507.3% gap
ABUS
522.2%
14.9%
CZWI
Higher net margin
CZWI
CZWI
3.6% more per $
CZWI
27.1%
23.5%
ABUS
Faster 2-yr revenue CAGR
CZWI
CZWI
Annualised
CZWI
1.9%
-13.2%
ABUS

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
ABUS
ABUS
CZWI
CZWI
Revenue
$10.7M
$15.8M
Net Profit
$2.5M
$4.3M
Gross Margin
Operating Margin
13.9%
31.0%
Net Margin
23.5%
27.1%
Revenue YoY
522.2%
14.9%
Net Profit YoY
112.7%
58.1%
EPS (diluted)
$0.01
$0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABUS
ABUS
CZWI
CZWI
Q4 25
$15.8M
Q3 25
$16.2M
Q2 25
$10.7M
$16.1M
Q1 25
$14.2M
Q4 24
$13.7M
Q3 24
$14.2M
Q2 24
$13.5M
Q1 24
$15.2M
Net Profit
ABUS
ABUS
CZWI
CZWI
Q4 25
$4.3M
Q3 25
$3.7M
Q2 25
$2.5M
$3.3M
Q1 25
$3.2M
Q4 24
$2.7M
Q3 24
$3.3M
Q2 24
$3.7M
Q1 24
$4.1M
Operating Margin
ABUS
ABUS
CZWI
CZWI
Q4 25
31.0%
Q3 25
27.9%
Q2 25
13.9%
25.1%
Q1 25
28.0%
Q4 24
24.5%
Q3 24
29.5%
Q2 24
35.0%
Q1 24
34.2%
Net Margin
ABUS
ABUS
CZWI
CZWI
Q4 25
27.1%
Q3 25
22.7%
Q2 25
23.5%
20.3%
Q1 25
22.5%
Q4 24
19.7%
Q3 24
23.1%
Q2 24
27.2%
Q1 24
26.9%
EPS (diluted)
ABUS
ABUS
CZWI
CZWI
Q4 25
$0.44
Q3 25
$0.37
Q2 25
$0.01
$0.33
Q1 25
$0.32
Q4 24
$0.28
Q3 24
$0.32
Q2 24
$0.35
Q1 24
$0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABUS
ABUS
CZWI
CZWI
Cash + ST InvestmentsLiquidity on hand
$37.4M
$118.9M
Total DebtLower is stronger
$0
$51.8M
Stockholders' EquityBook value
$83.0M
$187.9M
Total Assets
$103.3M
$1.8B
Debt / EquityLower = less leverage
0.00×
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABUS
ABUS
CZWI
CZWI
Q4 25
$118.9M
Q3 25
$82.4M
Q2 25
$37.4M
$67.5M
Q1 25
$100.2M
Q4 24
$50.2M
Q3 24
$36.6M
Q2 24
$36.9M
Q1 24
$28.6M
Total Debt
ABUS
ABUS
CZWI
CZWI
Q4 25
$51.8M
Q3 25
Q2 25
$0
Q1 25
Q4 24
$66.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABUS
ABUS
CZWI
CZWI
Q4 25
$187.9M
Q3 25
$186.8M
Q2 25
$83.0M
$183.5M
Q1 25
$180.1M
Q4 24
$179.1M
Q3 24
$180.1M
Q2 24
$176.0M
Q1 24
$172.8M
Total Assets
ABUS
ABUS
CZWI
CZWI
Q4 25
$1.8B
Q3 25
$1.7B
Q2 25
$103.3M
$1.7B
Q1 25
$1.8B
Q4 24
$1.7B
Q3 24
$1.8B
Q2 24
$1.8B
Q1 24
$1.8B
Debt / Equity
ABUS
ABUS
CZWI
CZWI
Q4 25
0.28×
Q3 25
Q2 25
0.00×
Q1 25
Q4 24
0.37×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABUS
ABUS
CZWI
CZWI
Operating Cash FlowLast quarter
$-15.7M
$11.7M
Free Cash FlowOCF − Capex
$10.4M
FCF MarginFCF / Revenue
65.9%
Capex IntensityCapex / Revenue
0.0%
8.3%
Cash ConversionOCF / Net Profit
-6.24×
2.74×
TTM Free Cash FlowTrailing 4 quarters
$17.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABUS
ABUS
CZWI
CZWI
Q4 25
$11.7M
Q3 25
$6.6M
Q2 25
$-15.7M
$-406.0K
Q1 25
$1.6M
Q4 24
$20.4M
Q3 24
$3.5M
Q2 24
$5.1M
Q1 24
$9.1M
Free Cash Flow
ABUS
ABUS
CZWI
CZWI
Q4 25
$10.4M
Q3 25
$6.2M
Q2 25
$-632.0K
Q1 25
$1.5M
Q4 24
$19.5M
Q3 24
$3.4M
Q2 24
$4.8M
Q1 24
$8.9M
FCF Margin
ABUS
ABUS
CZWI
CZWI
Q4 25
65.9%
Q3 25
38.4%
Q2 25
-3.9%
Q1 25
10.7%
Q4 24
142.2%
Q3 24
23.8%
Q2 24
35.7%
Q1 24
58.9%
Capex Intensity
ABUS
ABUS
CZWI
CZWI
Q4 25
8.3%
Q3 25
2.4%
Q2 25
0.0%
1.4%
Q1 25
0.7%
Q4 24
6.5%
Q3 24
0.9%
Q2 24
2.3%
Q1 24
1.4%
Cash Conversion
ABUS
ABUS
CZWI
CZWI
Q4 25
2.74×
Q3 25
1.80×
Q2 25
-6.24×
-0.12×
Q1 25
0.50×
Q4 24
7.55×
Q3 24
1.07×
Q2 24
1.39×
Q1 24
2.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons